The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: Role of hepatitis C and B infections
Abstract
Hepatologists are frequently asked to evaluate human immunodeficiency virus (HIV)-infected patients with abnormal liver enzymes and to assess the causal role of medications, such as antiretroviral drugs. Recently, the use of HIV-1 specific non-nucleoside reverse transcriptase inhibitors (NNRTIs), including nevirapine (NVP) and efavirenz (EFV), has been associated with severe hepatic injury. We prospectively studied the incidence of severe hepatotoxicity (grade 3 or 4 change in alanine or aspartate transaminase levels) among 568 patients receiving NNRTI-containing antiretroviral therapy, including 312 and 256 patients prescribed EFV and NVP, respectively. Hepatitis C virus (HCV) and hepatitis B virus (HBV) were detected in 43% and 7.7% of patients, respectively. Severe hepatotoxicity was observed in 15.6% of patients prescribed NVP and 8.0% of those prescribed EFV, but only 32% of NVP and 50% of EFV-associated episodes were detected during the first 12-weeks of therapy. The risk was significantly greater among persons with chronic viral hepatitis (69% of cases) and those prescribed concurrent protease inhibitors (PIs) (82% of cases). Nonetheless, 84% of patients with chronic HCV or HBV did not experience severe hepatotoxicity. Severe hepatotoxicity occurs throughout the course of NNRTI therapy and is more common among patients prescribed nevirapine, those coinfected with HCV or HBV, and those coadministered protease inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., & Holmberg, S. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381301 · Cited by 9,405
Medication Use and the Risk of Stevens–Johnson Syndrome or Toxic Epidermal Necrolysis
Roujeau, J.-C., Kelly, J. P., Naldi, L., Rzany, B., Stern, R. S., Anderson, T., Auquier, A., Bastuji-Garin, S., Correia, O., Locati, F., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512143332404 · Cited by 1,465
Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients
Benhamou, Y., Bochet, M., Di Martino, V., Charlotte, F., Azria, F., Coutellier, A., Vidaud, M., Bricaire, F., Opolon, P., Katlama, C., et al. (1999) · Hepatology · doi:10.1002/hep.510300409 · Cited by 1,219
The Natural History of Hepatitis C Virus Infection: Host, Viral, and Environmental Factors
Thomas, D. L., Astemborski, J., Rai, R. M., Anania, F. A., Schaeffer, M., Galai, N., Nolt, K., Nelson, K. E., Strathdee, S. A., Johnson, L., et al. (2000) · JAMA · doi:10.1001/jama.284.4.450 · Cited by 1,073
Self-citationStaszewski, S., Morales-Ramirez, J., Tashima, K. T., Rachlis, A., Skiest, D., Stanford, J., Stryker, R., Johnson, P., Labriola, D. F., Farina, D., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912163412501 · Cited by 993
Sulkowski, M. S. (2000) · JAMA · doi:10.1001/jama.283.1.74 · Cited by 950
Self-citationMarzolini, C., Telenti, A., Decosterd, L. A., Greub, G., Biollaz, J., & Buclin, T. (2001) · AIDS · doi:10.1097/00002030-200101050-00011 · Cited by 840
Montaner, J. S. G., Reiss, P., Cooper, D., Vella, S., Harris, M., Conway, B., Wainberg, M. A., Smith, D., Robinson, P., Hall, D., et al. (1998) · JAMA · doi:10.1001/jama.279.12.930 · Cited by 756
den Brinker, M., Wit, F. W. N. M., Wertheim-van Dillen, P. M. E., Jurriaans, S., Weel, J., van Leeuwen, R., Pakker, N. G., Reiss, P., Danner, S. A., Jan Weverling, G., et al. (2000) · AIDS · doi:10.1097/00002030-200012220-00011 · Cited by 390
Racial Differences in the Use of Drug Therapy for HIV Disease in an Urban Community
Moore, R. D., Stanton, D., Gopalan, R., & Chaisson, R. E. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403173301107 · Cited by 356
Self-citation
Cited by
Liver-Related Deaths in Persons Infected With the Human Immunodeficiency Virus: The D:A:D Study
(2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.15.1632 · Cited by 1,113
Andrade, R. J., Chalasani, N., Björnsson, E. S., Suzuki, A., Kullak-Ublick, G. A., Watkins, P. B., Devarbhavi, H., Merz, M., Lucena, M. I., Kaplowitz, N., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0105-0 · Cited by 924
van Leth, F., Phanuphak, P., Ruxrungtham, K., Baraldi, E., Miller, S., Gazzard, B., Cahn, P., Lalloo, U., van der Westhuizen, I., Malan, D., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15997-7 · Cited by 684
Konopnicki, D., Mocroft, A., de Wit, S., Antunes, F., Ledergerber, B., Katlama, C., Zilmer, K., Vella, S., Kirk, O., & Lundgren, J. D. (2005) · AIDS · doi:10.1097/01.aids.0000163936.99401.fe · Cited by 569
Soriano, V., Sulkowski, M., Bergin, C., Hatzakis, A., Cacoub, P., Katlama, C., Cargnel, A., Mauss, S., Dieterich, D., Moreno, S., et al. (2002) · AIDS · doi:10.1097/00002030-200204120-00001 · Cited by 444
Self-citationCorbett, E. L., Marston, B., Churchyard, G. J., & De Cock, K. M. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68383-9 · Cited by 438
Thein, H.-H., Yi, Q., Dore, G. J., & Krahn, M. D. (2008) · AIDS · doi:10.1097/qad.0b013e32830e6d51 · Cited by 409
Soriano, V., Puoti, M., Sulkowski, M., Cargnel, A., Benhamou, Y., Peters, M., Mauss, S., Bräu, N., Hatzakis, A., Pol, S., et al. (2007) · AIDS · doi:10.1097/qad.0b013e3281084e4d · Cited by 349
Self-citationRisk Factors for Idiosyncratic Drug-Induced Liver Injury
Chalasani, N., & Björnsson, E. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.04.001 · Cited by 347
Viral hepatitis and HIV coinfection
Sulkowski, M. S. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2007.11.009 · Cited by 316
Self-citationHepatotoxicity of antiretrovirals: Incidence, mechanisms and management
Núñez, M. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2005.11.027 · Cited by 313
Increasing burden of liver disease in patients with HIV infection
Joshi, D., O'Grady, J., Dieterich, D., Gazzard, B., & Agarwal, K. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62001-6 · Cited by 305
Central role of mitochondria in drug-induced liver injury
Pessayre, D., Fromenty, B., Berson, A., Robin, M.-A., Lettéron, P., Moreau, R., & Mansouri, A. (2012) · Drug Metabolism Reviews · doi:10.3109/03602532.2011.604086 · Cited by 277
Review article: drug hepatotoxicity
CHANG, C. Y., & SCHIANO, T. D. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03307.x · Cited by 264
Dore, G. J., Cooper, D. A., Pozniak, A. L., DeJesus, E., Zhong, L., Miller, M. D., Lu, B., Cheng, A. K., & Teams, T. 9. A. 9. S. (2004) · The Journal of Infectious Diseases · doi:10.1086/380398 · Cited by 253
Idiosyncratic drug-induced liver injury: an overview
Hussaini, S. H., & Farrington, E. A. (2007) · Expert Opinion on Drug Safety · doi:10.1517/14740338.6.6.673 · Cited by 183
Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines
Devarbhavi, H., Aithal, G., Treeprasertsuk, S., Takikawa, H., Mao, Y., Shasthry, S. M., Hamid, S., Tan, S. S., Philips, C. A., George, J., et al. (2021) · Hepatology International · doi:10.1007/s12072-021-10144-3 · Cited by 181
Incidence and risk factors of drug‐induced liver injury
Li, X., Tang, J., & Mao, Y. (2022) · Liver International · doi:10.1111/liv.15262 · Cited by 158
Stine, J. G., & Lewis, J. H. (2016) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2016.1127756 · Cited by 104
Metadata
- Authors
- Sulkowski, M. S., Thomas, D. L., Mehta, S. H., Chaisson, R. E., & Moore, R. D.
- Venue
- Hepatology
- Published
- 2002-01
- Volume
- 35
- Issue
- 1
- Pages
- 182-189
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2034482023
- Cited by
- 523
- References
- 35
- FWCI
- 29.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.